Invega Trinza 350 mg (Paliperidone (Paliperidone Palmitate) SUSPENSION (EXTENDED-RELEASE)) 350 MG

Invega Trinza 350 mg is an extended-release suspension of palperidone palmitate for intramuscular use. It is designed for long-term management of certain mental health conditions. This medication is administered by healthcare professionals to provide sustained symptom control.

Strength

350 MG

Pack Size

1.75ML

Manufacturer / TM Owner

JANSSEN INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Invega Trinza 350 mg is primarily used for the maintenance treatment of schizophrenia in adults who have been stabilized on palperidone palmitate. This extended-release suspension is designed to provide long-lasting effects, reducing the frequency of injections compared to other formulations. It is often used for individuals who require consistent management of their symptoms over an extended period.

Side Effects

Common effects of Invega Trinza 350 mg may include injection site reactions, weight gain, and changes in metabolism. Some individuals may experience drowsiness, dizziness, or restlessness. It is important to discuss any persistent or severe side effects with a healthcare provider.

Precautions & Warnings

Invega Trinza 350 mg should be administered by a healthcare professional experienced in the use of long-acting injectable antipsychotics. Regular monitoring is recommended to assess for potential side effects and to ensure the medication is working as intended. It is important to inform your healthcare provider about any other medications you are taking to avoid potential interactions.

Avoid Interactions

Invega Trinza 350 mg may interact with other medications, including those that affect the central nervous system, such as sedatives or antidepressants. Alcohol and certain over-the-counter medications may also interact with this suspension. Always consult a healthcare provider before starting or stopping any medication.

Frequently Asked Questions

Invega Trinza 350 mg is used for the maintenance treatment of schizophrenia in adults who have been stabilized on palperidone palmitate.

Invega Trinza 350 mg is typically administered once every three months by a healthcare professional.

Common side effects may include injection site reactions, weight gain, drowsiness, dizziness, and restlessness.

Invega Trinza 350 mg may interact with other medications, so it is important to consult a healthcare provider before combining it with other treatments.

Invega Trinza 350 mg is specifically formulated for adults with schizophrenia who have been stabilized on palperidone palmitate. Individual suitability should be determined by a healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.